[{"address1": "2001 Market Street", "address2": "Suite 3915 Unit #15", "city": "Philadelphia", "state": "PA", "zip": "19103", "country": "United States", "phone": "267 225 7416", "website": "https://www.contexttherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. Martin A. Lehr", "age": 39, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1984, "fiscalYear": 2022, "totalPay": 725250, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Minai-Azary", "age": 45, "title": "CFO & Treasurer", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": 533655, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex C. Levit Esq.", "age": 44, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": 512100, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Beck M.B.A.", "title": "Senior Vice President of Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.12, "open": 1.1, "dayLow": 1.1, "dayHigh": 1.18, "regularMarketPreviousClose": 1.12, "regularMarketOpen": 1.1, "regularMarketDayLow": 1.1, "regularMarketDayHigh": 1.18, "beta": 2.128, "volume": 46884, "regularMarketVolume": 46884, "averageVolume": 51667, "averageVolume10days": 47260, "averageDailyVolume10Day": 47260, "bidSize": 29200, "askSize": 900, "marketCap": 18361014, "fiftyTwoWeekLow": 0.47, "fiftyTwoWeekHigh": 1.69, "fiftyDayAverage": 1.10768, "twoHundredDayAverage": 1.11055, "currency": "USD", "enterpriseValue": -3316038, "floatShares": 13889029, "sharesOutstanding": 15966100, "sharesShort": 26979, "sharesShortPriorMonth": 32837, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0017, "heldPercentInsiders": 0.06861, "heldPercentInstitutions": 0.3006, "shortRatio": 1.46, "shortPercentOfFloat": 0.0018000001, "impliedSharesOutstanding": 15966100, "bookValue": 1.151, "priceToBook": 0.99913114, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -20751106, "trailingEps": -1.3, "enterpriseToEbitda": 0.151, "52WeekChange": 0.5217391, "SandP52WeekChange": 0.3219322, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "CNTX", "underlyingSymbol": "CNTX", "shortName": "Context Therapeutics Inc.", "longName": "Context Therapeutics Inc.", "firstTradeDateEpochUtc": 1634736600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "9370db4d-3fc8-33de-8dd0-aba14eeca611", "messageBoardId": "finmb_408000800", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.15, "targetHighPrice": 5.0, "targetLowPrice": 2.1, "targetMeanPrice": 3.7, "targetMedianPrice": 4.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 21677000, "totalCashPerShare": 1.358, "ebitda": -22009084, "quickRatio": 4.709, "currentRatio": 4.99, "returnOnAssets": -0.42303002, "returnOnEquity": -0.73512, "freeCashflow": -10797477, "operatingCashflow": -17750120, "financialCurrency": "USD", "trailingPegRatio": null}]